• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测人类乳腺癌内分泌治疗反应:一种假说。

Predicting response to endocrine therapy in human breast cancer: a hypothesis.

作者信息

Horwitz K B, McGuire W L

出版信息

Science. 1975 Aug 29;189(4204):726-7. doi: 10.1126/science.168640.

DOI:10.1126/science.168640
PMID:168640
Abstract

We hypothesize that the presence of progesterone receptors in human breast tumors may be a sensitive marker for predicting response to endocrine therapy. Progesterone receptors were found in 56 percent of tumors with estrogen receptors, but were absent in tumors without estrogen receptors. Preliminary clinical correlations show that only those breast tumors with progesterone receptors regressed after endocrine therapy.

摘要

我们推测,人类乳腺肿瘤中孕激素受体的存在可能是预测内分泌治疗反应的一个敏感标志物。在56%有雌激素受体的肿瘤中发现了孕激素受体,但在没有雌激素受体的肿瘤中则不存在。初步的临床相关性研究表明,只有那些有孕激素受体的乳腺肿瘤在内分泌治疗后出现消退。

相似文献

1
Predicting response to endocrine therapy in human breast cancer: a hypothesis.预测人类乳腺癌内分泌治疗反应:一种假说。
Science. 1975 Aug 29;189(4204):726-7. doi: 10.1126/science.168640.
2
Current status of estrogen and progesterone receptors in breast cancer.乳腺癌中雌激素和孕激素受体的现状
Cancer. 1977 Jun;39(6 Suppl):2934-47. doi: 10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p.
3
Prediction of breast cancer response to endocrine therapy.乳腺癌对内分泌治疗反应的预测。
Cancer Chemother Rep. 1974 Jul-Aug;58(4):513-9.
4
Comparison of sex steroid receptor analyses and carcinoembryonic antigen with clinical response to hormone therapy.
Cancer. 1980 Dec 15;46(12 Suppl):2846-50. doi: 10.1002/1097-0142(19801215)46:12+<2846::aid-cncr2820461423>3.0.co;2-9.
5
[Hormone dependence and the basis of hormone therapy in breast cancer].[激素依赖性与乳腺癌激素治疗的基础]
J Gynecol Obstet Biol Reprod (Paris). 1978 Mar;7(2):183-99.
6
New role of endocrine therapy in breast cancer.内分泌治疗在乳腺癌中的新作用。
Int J Radiat Oncol Biol Phys. 1978 May-Jun;4(5-6):469-72. doi: 10.1016/0360-3016(78)90082-2.
7
Current status of estrogen receptors in human breast cancer.
Cancer. 1975 Aug;36(2):638-44. doi: 10.1002/1097-0142(197508)36:2+<638::aid-cncr2820360805>3.0.co;2-s.
8
The prediction of hormonal dependency of mammary cancer.乳腺癌激素依赖性的预测。
Ann Surg. 1975 Sep;182(3):342-52. doi: 10.1097/00000658-197509000-00017.
9
[Experimental and clinical aspects of hormone therapy in breast cancer (author's transl)].
Arch Geschwulstforsch. 1981;51(7):623-9.
10
Predictability of response to endocrine ablation in breast cancer.乳腺癌内分泌消融治疗反应的可预测性
South Med J. 1975 Jun;68(6):714-6. doi: 10.1097/00007611-197506000-00013.

引用本文的文献

1
Association of progesterone receptor status with breast cancer prognosis: a meta-analysis.孕激素受体状态与乳腺癌预后的关联:一项荟萃分析。
World J Surg Oncol. 2025 Oct 2;23(1):356. doi: 10.1186/s12957-025-04001-y.
2
Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer.胰岛素样生长因子结合蛋白-6调节乳腺癌中孕酮介导的增殖拮抗作用。
Front Endocrinol (Lausanne). 2024 Dec 4;15:1450648. doi: 10.3389/fendo.2024.1450648. eCollection 2024.
3
Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis.
1990 年至 2019 年激素受体阳性乳腺癌女性发病率和生存率的变化趋势:一项大型基于人群的分析。
Sci Rep. 2024 Oct 10;14(1):23690. doi: 10.1038/s41598-024-74746-1.
4
Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+).ER(-)/PR(+) 激素受体状态的乳腺癌的临床病理特征和预后分析。
Front Endocrinol (Lausanne). 2023 Jul 19;14:1193592. doi: 10.3389/fendo.2023.1193592. eCollection 2023.
5
Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.利用雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌的临床病理变量预测Oncotype DX复发评分
J Breast Cancer. 2023 Apr;26(2):105-116. doi: 10.4048/jbc.2023.26.e19.
6
Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.术前接受新辅助化疗的激素受体阳性且人表皮生长因子受体2阴性乳腺癌患者的预后:一项回顾性分析。
Cancers (Basel). 2023 Feb 10;15(4):1157. doi: 10.3390/cancers15041157.
7
Nuclear Receptor Imaging In Vivo-Clinical and Research Advances.体内核受体成像——临床与研究进展
J Endocr Soc. 2022 Dec 31;7(3):bvac197. doi: 10.1210/jendso/bvac197. eCollection 2023 Jan 6.
8
CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3.CAXII是一种由雌激素受体(ER)和GATA3调节的管腔型乳腺肿瘤的替代标志物。
Cancers (Basel). 2022 Nov 6;14(21):5453. doi: 10.3390/cancers14215453.
9
Multiregional Radiomic Signatures Based on Functional Parametric Maps from DCE-MRI for Preoperative Identification of Estrogen Receptor and Progesterone Receptor Status in Breast Cancer.基于动态对比增强磁共振成像功能参数图的多区域放射组学特征用于乳腺癌雌激素受体和孕激素受体状态的术前识别
Diagnostics (Basel). 2022 Oct 21;12(10):2558. doi: 10.3390/diagnostics12102558.
10
Prognostic Factors for Bone Survival and Functional Outcomes in Patients With Breast Cancer Spine Metastases.乳腺癌脊柱转移患者的骨生存和功能结局的预后因素。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221122642. doi: 10.1177/15330338221122642.